Van ECK Associates Corp Sells 10,815 Shares of Agilent Technologies, Inc. $A

Key Points

• Van ECK Associates Corp trimmed its stake in Agilent by 0.4%, selling 10,815 shares and ending the quarter with 3,007,863 shares (about 1.06%) valued at $386,059,000.
• Agilent agreed to acquire Biocare Medical for $950 million in an all‑cash deal, a strategic bolt‑on to expand its diagnostics business that has drawn mixed market reactions and raised near‑term integration and liquidity concerns.
• Agilent slightly missed Q1 estimates (EPS $1.36 vs $1.37; revenue $1.80B vs $1.81B), set FY26 guidance of 5.900–6.040 EPS, and carries a MarketBeat consensus of Moderate Buy with a $161.20 target; it also announced a $0.255 quarterly dividend (0.9% yield).

Van ECK Associates Corp trimmed its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 0.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,007,863 shares of the medical research company's stock after selling 10,815 shares during the quarter. Van ECK Associates Corp owned approximately 1.06% of Agilent Technologies worth $386,059,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new stake in Agilent Technologies in the second quarter worth $395,088,000. AQR Capital Management LLC boosted its stake in shares of Agilent Technologies by 424.1% during the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company's stock valued at $240,956,000 after purchasing an additional 1,652,244 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Agilent Technologies by 132.2% in the second quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company's stock worth $277,807,000 after purchasing an additional 1,340,161 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Agilent Technologies by 10.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company's stock worth $1,560,964,000 after purchasing an additional 1,273,994 shares during the last quarter. Finally, Troy Asset Management Ltd increased its stake in Agilent Technologies by 74.3% in the 2nd quarter. Troy Asset Management Ltd now owns 2,397,820 shares of the medical research company's stock worth $282,967,000 after buying an additional 1,021,865 shares during the period.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HSBC assumed coverage on shares of Agilent Technologies in a research note on Tuesday, January 20th. They issued a "buy" rating and a $180.00 target price on the stock. Evercore upgraded Agilent Technologies from an "in-line" rating to an "outperform" rating and boosted their price target for the company from $155.00 to $160.00 in a report on Monday, January 5th. UBS Group dropped their price objective on Agilent Technologies from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. Robert W. Baird raised their price objective on Agilent Technologies from $142.00 to $165.00 and gave the stock an "outperform" rating in a report on Tuesday, November 25th. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Agilent Technologies in a research report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $161.20.

Agilent Technologies Price Performance

Shares of A opened at $116.57 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.59 and a current ratio of 2.07. The company has a 50 day moving average price of $132.22 and a 200-day moving average price of $136.12. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $160.27. The stock has a market capitalization of $32.94 billion, a PE ratio of 25.73, a PEG ratio of 2.42 and a beta of 1.31.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing analysts' consensus estimates of $1.37 by ($0.01). The business had revenue of $1.80 billion during the quarter, compared to the consensus estimate of $1.81 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The business's quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the firm earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. Equities analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 22nd. Investors of record on Tuesday, March 31st will be paid a dividend of $0.255 per share. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, March 31st. Agilent Technologies's dividend payout ratio is 22.52%.

Trending Headlines about Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Deal strengthens diagnostics/clinical pathology exposure — Biocare is a global leader in IHC/ISH/FISH reagents and consumables, giving Agilent a complementary product set and recurring-revenue mix that can boost long-term growth in its diagnostics segment. Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
• Positive Sentiment: Strategic, bolt-on M&A at scale — $950M is modest versus Agilent’s ~$33B market cap and could be earnings-accretive over time if integration and cross‑sell succeed. Analysts see this as a targeted expansion of addressable market. Agilent to acquire Biocare Medical in $950 million all-cash deal
• Neutral Sentiment: Transaction structure and sellers — deal is all-cash and agreed with private equity owners Excellere Partners and GHO Capital; closing remains subject to customary conditions. This clarifies counterparties but not timing. Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies
• Neutral Sentiment: Mixed market signals — several outlets note an immediate positive headline reaction (shares rising on the deal) while others highlight muted enthusiasm; expect short-term volatility as investors weigh strategic benefits vs. recent results. Agilent stock rises on $950M Biocare Medical acquisition
• Negative Sentiment: Acquisition fails to offset recent earnings miss — Agilent’s Q1 slightly missed estimates (EPS $1.36 vs $1.37) and its FY26 guidance was modest; some coverage says the buyout didn’t restore investor confidence, producing premarket weakness. Agilent stock slips premarket: $950M Biocare buyout fails to lift investor sentiment after Q1 miss
• Negative Sentiment: Cash outlay and integration risk — the all-cash purchase reduces liquidity and introduces integration/execution risk; near-term margin or leverage pressure is a possible headwind until synergies are realized. Agilent Buys Medical Instruments Maker Biocare for $950 Million

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.